Nuvaxovid™, vacina contra a COVID-19, é a primeira opção à base de proteína para adolescentes com idade entre 12 e 17 anos na Europa GAITHERSBURG, Md., 6 de julho de 2022 /PRNewswire/ — A Novavax, Inc. (Nasdaq: NVAX), uma empresa de biotecnologia dedicada ao desenvolvimento e à…
Related Posts
Michael J. Kennedy named to Hawaiian Electric Industries board of directors
HONOLULU, July 19, 2022 /PRNewswire/ — Michael J. Kennedy, an innovative leader with extensive executive and strategy experience with national…
BioCina announces opening of new GMP plasmid DNA manufacturing suite
SAN DIEGO and ADELAIDE, Australia, June 13, 2022 /PRNewswire/ — BioCina, a leading contract development and manufacturing organization (CDMO) today…
Sulfuric Acid Market worth $28.5 Billion by 2027 – Exclusive Report by MarketsandMarkets™
CHICAGO, Sept. 2, 2022 /PRNewswire/ — Sulfuric Acid Market is projected to grow from USD 13.2 billion in 2020 to…